prostate cancer
Phase III trial initiated for enzalutamide in treatment of prostate cancer
March 24, 2016Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer
Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …
NICE approves Janssen’s Zytiga for prostate cancer before chemo
March 21, 2016Sales and Marketing Janssen, NICE, Zytiga, prostate cancer
The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat …
Janssen’s Zytiga boosts survival in early-stage prostate cancer
March 14, 2016Research and Development, Sales and Marketing Janssen, Zytiga, abiraterone, prednisone, prostate cancer
Janssen has announced data from a post-hoc analysis of a Phase III trial showing that Zytiga plus prednisone boosted overall …
AZ’s Lynparza gets prostate cancer breakthrough status
January 28, 2016Sales and Marketing AstraZeneca, Breakthrough Therapy Designation, FDA, lynparza, olaparib, prostate cancer
AstraZeneca’s Lynparza has been granted breakthrough therapy designation by the FDA as a monotherapy for the treatment of a specific …
Trial launched to test exercise as prostate cancer treatment
January 6, 2016Research and Development Cancer Research UK, active surveillance, exercise, prostate cancer
Cancer Research UK has launched a study to determine if exercise could help men with prostate cancer, the UK’s most …
NICE publishes draft guidance on two prostate cancer treatments
December 11, 2015Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer
NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
NICE decision restricts Bayer’s Xofigo to select prostate cancer patients
November 19, 2015Research and Development, Sales and Marketing Bayer, NICE, prostate cancer
NICE has issued its Final Appraisal Determination (FAD) recommending Bayer’s Xofigo (radium-223 dichloride) for use on the NHS in England …
New cancer medicines approved in Scotland, available via NHS
October 12, 2015Sales and Marketing Scottish Medicines Consortium, Zytiga, abiraterone acetate, prostate cancer
The Scottish Medicines Consortium (SMC) has today recommended Janssen’s Zytiga (abiraterone acetate) for use before chemotherapy in men with advanced …
Yervoy setback in prostate cancer
September 16, 2013Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer
Prostate cancer drug Xtandi gets nod
April 26, 2013Sales and Marketing Xtandi, Zytiga, prostate cancer
Astellas and Medivation have received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) for Xtandi, …
Dendreon slashes staff and closes facility
July 31, 2012Manufacturing and Production, Sales and Marketing Dendreon, M&P, Provenge, prostate cancer
Cancer vaccine specialist Dendreon has said it will slash 600 jobs and close one of its three manufacturing facilities in …
New chairman of the board for Dendreon
July 5, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Dendreon, Provenge, johnson, prostate cancer
Dendreon has announced that its president and chief executive John Johnson has assumed the additional title of chairman of the …
Price cut sways NICE on Zytiga
May 16, 2012Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer
NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance. In its final guidance, the watchdog is recommending …
UK government invests in new radiotherapy treatment
April 16, 2012Sales and Marketing Cancer, Photon beam therapy, Proton beam therapy, prostate cancer, radiotherapy
The government is to invest £250 million in a cutting-edge radiotherapy treatment that should benefit 1,500 cancer patients in the …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
